You just read:

Grünenthal has Acquired US-based Thar Pharmaceuticals Inc. to Expand its Development Portfolio of Treatment Options for CRPS (Complex Regional Pain Syndrome), a Serious, Disabling Orphan Disease

News provided by

Grünenthal Group

Nov 16, 2016, 14:31 ET